BRAVO MULTINATIONAL INCORPORATED (BRVO) GENERATES REVENUE FROM NEW CASINO GAMING BUSINESS VENTURE IN NICARAGUA

Toronto, Canada –June 29, 2016– Bravo Multinational Incorporated (BRVO: OTCQB) completed an acquisition transaction on May 6, 2016, with Centro de Entretenimiento y Diversion Mombacho S.A., located in Managua, Nicaragua.  On June 1, 2016, Bravo received its first income from this new business venture, with additional income payments to be received on the first of each month.

In the above transaction, BRVO purchased 150 of a total contracted 500 slot machines and video poker gaming machines. All machines are to be operated and managed under a long-term (the year 2033) countrywide national license.  An announcement regarding the next gaming machine purchase installment will be released in an upcoming press release.

BRVO’s income stream from these gaming machines may come from three sources.  Firstly, the historical date shows gross net-win income per machine at approximately $420 US per month.  Secondly, BRVO has the option to sell the machines to any third party for a profit.  The Company’s cost per machine is $4500 and based on historical data, the retail value of a machine which has been placed into a licensed vendor location is approximate $7000 per machine.  Finally, when machines are sold, BRVO, in addition to the retail profit margin, would also receive fees for arranging and managing the North American side of the transaction.

BRVO hired Gametouch, LLC to manage the potential sales of machines, www.gametouchllc.com.

The Company executives remain confident that this transaction is a solid financial move, providing a long-term steady revenue source for Bravo Multinational Incorporated.

All incomes will be reported in BRVO’s required US SEC filings.

Please visit the new Bravo Multinational Incorporated website :www.bravomultinational.com.

About Bravo Multinational Incorporated:

Bravo Multinational Incorporated (OTCQB: BRVO) is a diversified Company, with casino equipment holdings in Central and South America as well as gold / silver mining properties and claims in North America. Bravo’s growth strategy, driven by partnerships, acquisitions, and new ventures should result in financially viable and profitable corporate divisions.

For further information about Bravo Multinational Incorporated, please contact, Kara Craig, YES INTERNATIONAL, 757-306-6090, yes@yesinternational.com, www.yesinternational.com and www.bravomultinational.com

Bravo Multinational Incorporated cautions that the statements made in this press release and other forward looking statements made on behalf of the Company may be affected by such other factors including, but not limited to, vagaries of trade, market competition and other risks detailed herein and from time to time in the U.S. Securities and Exchange Commission filings of the Company.

Bravo Multinational Incorporated (BRVO) Reports on Lawsuit Dismissal

 

Toronto, Canada –June 27, 2016- Bravo Multinational Incorporated (BRVO: OTCQB) reports a lawsuit filed in Chancery Court in Delaware against Bravo Multinational Incorporated and its board that was reported in our recent 10-Q, has been dismissed as of June 24, 2016.

Paul Parliament, Bravo Multinational’s President, stated, “ We are very pleased with this timely dismissal, allowing the company to now move on unencumbered with its business objectives and plans. The BRVO executives would like to thank its legal team in Delaware, lead by Mr. Chris Adamopoulos, as well as, the Company’s counsel, Mr. Norman Reynolds, for their diligence and commitment, resulting in the dismissal. Also, Bravo will be holding its annual shareholders’ meeting in the very near future, and will be announcing the date and location, shortly.”

BRVO continues to work forward on all aspects of its operational growth and will announce on its progress as information becomes available.

Please visit our new website at:   WWW. BRAVOMULTINATIONAL.COM

About Bravo Multinational Incorporated:

Bravo Multinational Incorporated (OTCQB: BRVO) is a diversified Company, with casino equipment holdings in Central and South America, as well as, gold / silver mining properties and claims in North America. Bravo’s growth strategy, driven by partnerships, acquisitions, and new ventures should result in financially viable and profitable corporate divisions.

For further information about Bravo Multinational Incorporated please contact, Kara Craig, YES INTERNATIONAL, 757-306-6090 or yes@yesinternational.com.

Bravo Multinational Incorporated cautions that the statements made in this press release and other forward looking statements made on behalf of the Company may be affected by such other factors including, but not limited to, vagaries of trade, market competition and other risks detailed herein and from time to time in the U.S. Securities and Exchange Commission filings of the Company.

Predictive Technology Group, Inc. (PRED) Announces Key Patent Issuance by US Patent and Trademark Office For Treating Patients with Genetic Spinal Deformities and Syndromes

Award Provides Patent Protection for Multiple Therapeutic and Companion Diagnostic Products

Salt Lake City, UT –June 21, 2016– Predictive Technology Group, Inc. (OTC PINK: PRED), a life sciences technology holding company, announced today that the United States Patent and Trademark Office (USPTO) has granted a fundamental patent (US Patent 9,370,431) that covers the practice of administering ANY spine deformation therapeutics to a patient having a spine deformation altered risk associated biomarker.

“We are pleased to see this latest patent issuance that supports PRED’s novel approach to diagnosing spinal disorders and syndromes,” said Mike Schramm, PRED’s Director of Intellectual Property. “This issued US patent supports the commercial use of both our diagnostic and next-generation companion treatment products.” The claims of the ‘431 application build on previously issued US patents 8,123,787 and 8,641,738 to which ‘431 claims priority and further bolster PRED’s Intellectually Property position.

“We are gratified to see this latest patent issuance, which covers the core technology underlying the Company’s first available molecular diagnostic test,” said Bradley Robinson, President and Chief Executive Officer of Predictive Technology Group, Inc. “Furthermore, this fundamental patent covers not only spinal applications of our technology but establishes a precedent for the other patent applications that have been submitted on the Company’s portfolio of next-generation diagnostic and companion treatment products.”

The patent establishes the foundation of key intellectual property (IP) covering ANY treatment options (drug, surgery, bracing, etc.) for patients having a specific spine deformity biomarker.  This newly issued patent is additive to previously announced patents.  Furthermore, the Company has additional US and International patent applications pending and will pursue such applications with the objective of receiving additional issued patents in several other disease states.

The issuance of this new patent is a significant milestone for PRED.

For information about this release, contact Rich Kaiser, Investor Relations, YES INTERNATIONAL, 757-306-6090, yes@yesinterntional.com, and info@predictivetechnologygroup.com.

 About Predictive Technology Group, Inc.

Predictive Technology Group, Inc. (PRED), through its wholly owned subsidiaries, revolutionizes the treatment of serious and debilitating diseases through the commercialization of novel therapeutics leveraged by proprietary gene-based companion diagnostics. The Company develops and/or acquires proprietary technologies that open windows into the origin of human disease and the role that genes and their related proteins play in diseases’ onsets and progressions. PRED’s subsidiaries use gene-based information as cornerstones in the development of new diagnostics that assess a person’s risk of disease and therapeutic products designed to prevent effectively and/or treat diseases.

Forward-Looking Statements

To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.

 

Predictive Technology Group Appoints Mike Dey as Chief Executive Officer of Predictive Therapeutics

Former Wyeth Women’s Health Executive is Focused on Commercialization of DNA Diagnostic Tests and Companion Therapeutics for Endometriosis  

Salt Lake City, UT — (June 1, 2016) — Predictive Technology Group, Inc. (OTC PINK: PRED), announced today that Michael Dey, Ph.D. has been named Chief Executive Officer of Predictive Therapeutics, a wholly-owned subsidiary of Predictive Technology Group, Inc. Dr. Dey will lead the efforts to advance the commercialization of Predictive’s women’s health products.

Previous to joining Predictive Therapeutics, Dr. Dey was an executive at Wyeth where he was the President of Scientific Affairs for Wyeth’s Women’s Health Care business.  Prior, Mike was the President of Wyeth Women’s Health Care which he managed for 7 years. Dr. Dey had worldwide responsibility for this consolidated unit of more than $3 billion annually that included all of Wyeth’s Women’s Health Care resources globally.

Prior to his leadership role in women’s health care Mike served as Vice President, General Manager of ESI Pharma, Inc. In 1995, with Wyeth’s acquisition of American Cyanamid and Lederle Standard Products, Mike became President of ESI Lederle, Inc.  As President of ESI Lederle, Mike’s responsibilities included directing one of the largest generic companies in the U.S. with more than $500 million in sales, approximately 150 people in R&D and 100 people in Marketing and Sales. ESI Lederle sold both oral and injectable products that included Tubex®, the prefilled syringe delivery system.

Mike received an undergraduate degree in Biology/Chemistry in 1973, a Master’s Degree in 1980 in Pharmacology and Toxicology and a Ph.D. in 1984 in Pharmacology and Toxicology.

Predictive Therapeutics plans to launch several new molecular diagnostic tests focused on women’s health, and a therapeutic drug for the treatment of endometriosis. Dr. Dey’s appointment will assist Predictive to effectively reach these commercial milestones.

About Predictive Technology Group, Inc.

Predictive Technology Group, Inc. (PRED), through its wholly owned subsidiaries, revolutionizes the treatment of severe and debilitating diseases through the commercialization of novel therapeutics leveraged by proprietary gene-based companion diagnostics. The Company develops and acquires proprietary technologies that open windows into the origin of human illness and the role that genes and their related proteins play in diseases’ onsets and progressions. PRED’s subsidiaries use gene-based information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to prevent and treat diseases effectively, www.predictivetechnologygroup.com and www.predrx.com.

For further information, contact Rich Kaiser, Investor Relations, YES INTERNATIONAL, 757-306-6090 and yes@yesinternational.com and info@predicitivetechnologygroup.com.

Forward-Looking Statements

To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.

 

SoOum Corp (SOUM) Signs Letter of Intent to Acquire Western Grade LLC, A Well-established Industrial Construction Company

New York, New York– June 13 2016– SoOum Corp.  (OTCPINK: SOUM) announces it has signed a “Letter of Intent” to acquire Western Grade LLC.   Based in the Southwest United States, Western Grade is a prominent general contractor in the region. The company specializes in underground utilities site improvement and construction, excavating, paving, transport, earth moving, water movement/supply and more.

The proposed acquisition of Western Grade would bring SoOum a step towards a multi-industry Corporation. Western Grade’s expertise and mission of water supply and delivery through large scale project management in canals, pipeline supply, and innovative water supply project management are noteworthy. A Western Grade acquisition greatly reinforces SoOum’s pursuit of its ultimate mission of “Addressing Shortages and Minimizing Scarcity.”

As negotiations continue in earnest, SoOum’s and Western Grade’s management teams proceed with the ultimate goal of an acquisition of Western Grade, LLC into SoOum Corp.

About Western Grade

Founded in 2001, and still growing, Western Grade’s dedication, commitment to success and outstanding customer service were, and still remain a leading catalyst for the company’s growth.  Today, Western Grade is a well respected Industrial Contractor, with unsurpassed expertise and state of the art technical capabilities.

About SoOum Corp.

SoOum Corp. is a publicly held (OTCPINK:SOUM) Physical Commodities Trading firm.  Specializing in arbitrage based transactions of Physical Commodities, as well as offering an e-commerce Trading Platform, allowing customers to be a part of a unique community of Physical Commodities Traders, Suppliers, Buyers, and Procurement Agents engaging in the purchasing and selling of Products and Commodities across the globe: www.sooum.com/investor-relations

For inquiries into this matter please contact SoOum at www.sooum.com/investor-relations  or reach Rich Kaiser, Business Consultant, YES INTERNATIONAL, 757-306-6090 and/or yes@yesinternational.com

Cautionary Note Regarding Forward Looking Statement

Statements in this press release regarding the Company’s business which are not historical facts are “forward-looking statements” that involve a number of risks and uncertainties.  The Company cautions that various factors, including the factors described under the caption forward-looking statements in the Company’s annual report on Form 10-K, could cause actual results to differ materially from the statements contained herein. These factors include the following:  business conditions and  volatility in the commodities market, and the general economy; competitive factors including compressed gross profit margins; shifts in market demand; product availability; reliance on key customers; fluctuations in foreign currency exchange rates; income tax legislation; and the risk factors listed from time to time in the Company’s reports filed with the Securities and Exchange Commission.  The Company undertakes no obligation to update any forward-looking statement.

Northstar Electronics, Inc. Announces Quarterly Updates through Shareholder Interactive Calls

VIRGINIA BEACH, VA / June 7, 2016 / Northstar Electronics, Inc. (OTC PINK: NEIK), a system development company, working primarily in the aviation, defense, and marine industries is pleased to announce that it is initiating live quarterly updates by management to shareholders on the operations of the Company and its most recent developments.

The first interactive call is scheduled for July 8, 2016 at 4:30 PM EDT / 1:30 PM PDT. One week prior to the scheduled call we will provide shareholders with the call-in information and name of our guest moderator.

Communication with our shareholders has always been very important to us and we encourage them to participate as they are a vital part of our company’s future.

For further information about this release, contact, Rich Kaiser, Investor Relations, Yes International, 757-306-6090,yes@yesinternational.com.

About Northstar Electronics, Inc.

Northstar was established in the late 1990’s. The Company has carried out design and manufacturing contracts for various divisions of Lockheed Martin Corp., including LM MS2 ( Submarine Command and Control Consoles), LM Canada (Naval Anti-Terrorism System), LM Aeronautics (Mechanical parts for the P-3 Orion Airplane), and L-3 (Navy Frigate Command and Control Consoles). Northstar also designed, manufactured, and sold its own sonar-based system to commercial customers.

In the past few years, we have worked towards re-establishing the company in the key areas in which it has excelled in the past and, thereby, to grow the company bigger and stronger than it was previously. To that end, we have brought together a team of world-class professionals who are fully dedicated to Northstar’s success.

Website (under construction at this time): www.northstarelectronics.com.

Safe Harbor Statement:

This press release may include predictions, estimates, opinions or statements that might be considered “forward-looking” under the provisions of the Private Securities Litigation Reform Act of 1995. Such statements generally can be identified by phrases such as the Company or its management “believes,” “expects,” “anticipates,” “foresees,” “forecasts,” “estimates,” or other, similar words or phrases.

PREDICTIVE TECHNOLOGY GROUP, INC. FORMS PREDICTIVE WOMEN’S HEALTH SUBSIDIARY

Salt Lake City, UT- June 6, 2016- Predictive Technology Group, Inc. (OTCPINK:PRED) announces the formation of a new wholly-owned subsidiary, Predictive Women’s Health.

Predictive Women’s Health is an entity that will concentrate on providing innovative treatments and solutions for women.

Management intends to focus its resources and technologies on improving patient outcomes for women.

For further information about PRED, contact Rich Kaiser, Investor Relations, YES INTERNATIONAL, 757-306-6090, rich@yesinternational.com and info@predictivetechnologygroup.com

About Predictive Technology Group, Inc.

Predictive Technology Group, Inc. (OTC PINK: PRED), through its wholly owned subsidiaries, revolutionizes the treatment of severe and debilitating diseases through the commercialization of novel therapeutics leveraged by proprietary gene-based companion diagnostics. The Company develops and/or acquires proprietary technologies that open windows into the origin of human disease and the role that genes and their related proteins play in diseases’ onsets and progressions. PRED’s subsidiaries use gene-based information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to prevent and treat diseases.

Forward-Looking Statements

To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment and other risks the Company may identify from time to time in the future.

Predictive Technology Group Announces Name Change of its Subsidiary LifeCode Genetics to Predictive Diagnostics

LifeCode Genetics Changes Name to Predictive Diagnostics

Salt Lake City, UT — (June 2, 2016) – Predictive Technology Group, Inc. (OTC PINK: PRED) announced today that LifeCode Genetics, a wholly-owned subsidiary of Predictive Technology Group, Inc., is changing its name to Predictive Diagnostics.

Bradley Robinson, President, Predictive Technology Group, Inc., states, “the name change of LifeCode Genetics to Predictive Diagnostics is to align its mission and branding in preparation for commercialization of its initial diagnostic.”

About Predictive Technology Group, Inc.

Predictive Technology Group, Inc. (PRED), through its wholly owned subsidiaries, revolutionizes the treatment of severe and debilitating diseases through the commercialization of novel therapeutics leveraged by proprietary gene-based companion diagnostics. The Company develops and acquires proprietary technologies that open windows into the origin of human illness and the role that genes and their related proteins play in diseases’ onsets and progressions. PRED’s subsidiaries use gene-based information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to prevent and treat diseases effectively, www.predictivetechnologygroup.com and www.predrx.com.

For further information, contact Rich Kaiser, Investor Relations, YES INTERNATIONAL, 757-306-6090 and yes@yesinternational.com and info@predicitivetechnologygroup.com.

Forward-Looking Statements

To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.

 

Forward-Looking Statements

To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the